Novo Nordisk, Eli Lilly sued over weight loss drugs and vision loss
Novo Nordisk and Eli Lilly face lawsuits over alleged vision loss linked to their weight loss drugs, Ozempic and Wegovy. Over 90 cases have been filed in New Jersey, with additional lawsuits in federal court. Both companies deny the claims, citing lack of evidence. Studies show mixed results on the drugs' connection to NAION. The EMA has added warnings in Europe, while the FDA is investigating.
How this was made
The 30-second read
Why it matters
For NVO and LLY, the key trading variable is the unresolved FDA assessment and the litigation trajectory, which can shift perceived safety risk and potential labeling exposure.
Market read
This is a safety-and-litigation headline with an explicit U.S. regulatory overhang, likely to drive volatility around GLP-1 risk narratives.
What to watch
NAION diagnosis/tracking limitations and high baseline risk in patients with diabetes, heart disease, hypertension, and sleep apnea complicate attribution, which may reduce the likelihood of immediate label escalation in the U.S.
Background
The article centers on NAION (nonarteritic anterior ischemic optic neuropathy) alleged as a side effect of Ozempic and Wegovy (semaglutide) and related weight-loss drugs, with mixed scientific studies and differing regulatory stances.
Ticker impact
Novo Nordisk is named as a defendant in NAION lawsuits tied to Ozempic and Wegovy, with FDA review and EU labeling actions mentioned.
Near-term volatility risk, with downside skew if FDA action or adverse evidence gains traction.
The article highlights ongoing FDA assessment, EU labeling changes, and multiple lawsuits alleging NAION causality, which can affect risk perception even without a ruling yet.
Eli Lilly is named alongside Novo Nordisk in federal and state NAION lawsuits alleging vision loss after weight-loss drug use.
Potential downside bias until FDA conclusions and court developments clarify causality and labeling needs.
The piece cites mixed studies, FDA investigation since late 2024, and filings stating studies do not prove causation, implying an unresolved but headline-sensitive risk.
Market effects
Reinforces headline risk for GLP-1 weight-loss drugs, potentially affecting broader sentiment and labeling expectations across the class.
EU labeling already moved further than the U.S., which can influence global investor expectations for U.S. label outcomes.
Cross-border regulatory actions and compensation awards (e.g., Denmark) can raise the probability of similar scrutiny elsewhere.
Counterpoint
Companies dispute causality and cite a company-funded study showing no increased NAION risk; without FDA-required U.S. labeling, the market may overreact to allegations.
Key entities
- companyNovo Nordisk
Defendant in NAION lawsuits tied to Ozempic and Wegovy; cites a company-funded study and says it is defending the claims.
- companyEli Lilly
Named in federal lawsuits alongside Novo; states patient safety is top priority and that studies do not prove causation.
- regulatorFDA
Investigating a potential NAION link since late 2024 and will decide whether regulatory action is warranted after its assessment.
- regulatorEuropean Medicines Agency (EMA)
Determined NAION should be listed as a very rare side effect of semaglutide and called for label warnings in Europe.
